Nancy Kamel, MD
Family Medicine · Virginia Beach, VANPI 1477852952
Payments from drug & device makers
Across 232 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$769
- Esperion Therapeutics, Inc.$644
- Novo Nordisk$591
- AbbVie$417
- Lilly USA, LLC$349
- Pfizer$348
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,26487%
- Education$61913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $769 |
| Esperion Therapeutics, Inc. | 15 | $644 |
| Novo Nordisk | 23 | $591 |
| AbbVie(2 entities) | 24 | $417 |
| Lilly USA, LLC | 22 | $349 |
| Pfizer | 19 | $348 |
| GSK | 16 | $295 |
| Amgen(2 entities) | 10 | $159 |
| Boehringer Ingelheim | 8 | $153 |
| Abbott | 5 | $110 |
| Sanofi-aventis U.S. LLC | 6 | $95 |
| Dexcom, Inc. | 5 | $90 |
| Biohaven Pharmaceuticals, Inc. | 1 | $77 |
| Amarin Pharma, Inc. | 4 | $66 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $66 |
| Bayer | 4 | $61 |
| Merck | 3 | $51 |
| Genentech USA, Inc. | 1 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Endo Pharmaceuticals Inc. | 2 | $47 |
| Boston Scientific | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Azurity Pharmaceuticals, Inc. | 2 | $39 |
| Irhythm Technologies, Inc. | 2 | $36 |
| Sanofi Pasteur Inc. | 1 | $34 |
| Astellas Pharma US Inc | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Tris Pharma Inc | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Seqirus USA Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,883 in reported general payments places this provider in the 85th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $58,007 |
| JardianceEmpagliflozin | 45 | $47,602 |
| EliquisApixaban | 28 | $36,085 |
| MounjaroTirzepatide | 22 | $29,932 |
| TrulicityDulaglutide | 20 | $26,610 |
| XareltoRivaroxaban | 19 | $24,231 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $16,492 |
| JanuviaSitagliptin Phosphate | 19 | $15,916 |
| LinzessLinaclotide | 11 | $9,847 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,405 |
| Humulin N KwikpenInsulin Nph Human Isophane | 11 | $2,878 |
| Atorvastatin Calcium | 314 | $2,624 |
| Metoprolol Succinate | 139 | $2,120 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $1,995 |
| Duloxetine Hcl | 77 | $1,902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $591 | $58,00746 claims |
| Lilly USA, LLCMounjaro, Trulicity | $349 | $56,54242 claims |
| Boehringer IngelheimJardiance | $153 | $47,60245 claims |
| PfizerEliquis | $348 | $36,08528 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $295 | $20,89837 claims |
| MerckJanuvia | $51 | $15,91619 claims |
| AbbVieLinzess, Synthroid | $417 | $10,61132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Virginia Beach
- Gregory HaaseVirginia Beach$517K
- Ted KubickiVirginia Beach$159K
- Jim-David GaglioneVirginia Beach$24K
- Michael CharlesVirginia Beach$18K
- Glenn McDermottVirginia Beach$18K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.